The acute coronary syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into unstable angina, ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), and others.
On the basis of diagnosis, the market is categorized into blood tests, imaging, stress test, and others. The imaging segment is sub-segmented into Myocardial Perfusion Imaging (MPI), Computerized Tomography (CT) angiogram, echocardiogram, coronary angiogram, and others.
On the basis of treatment, the market is segmented into medication, surgery, and others. The medication segment is sub-segmented into thrombolytics, nitroglycerin, antiplatelet drugs, beta blockers, statins, surgery, and others. The antiplatelet drugs segment is further segmented into aspirin, clopidogrel, prasugrel, and others. The beta blockers segment is further segmented into metoprolol, nadolol, and others. The statins segment is further segmented into atorvastatin, simvastatin, and others. The surgery segment is sub-segmented into angioplasty and stenting, coronary bypass surgery, and others.
On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.
The Americas dominates the acute coronary syndrome market owing to the rising prevalence of coronary heart diseases and presence of a well-developed healthcare sector within the region. Moreover, increasing healthcare expenditure and presence of market players within the region boost the market.
Europe stands second in the acute coronary syndrome market due to the increasing availability of funds for research, a huge patient population, and a well-developed healthcare sector. According to the Heart U.K., there were approximately 404,000 hospital admissions due to coronary heart diseases in England during 2012 to 2013. Moreover, growing geriatric and obese population provides favorable backgrounds for market growth within the region.
Asia Pacific is the fastest growing region for the market due to the presence of developing economies such as India, China, Australia, and others within the region. Moreover, a huge patient population, rising healthcare expenditure, and a rapidly developing healthcare sector fuel the market growth.
The Middle East and Africa has the least share in the acute coronary syndrome market. This can be attributed to the low per capita healthcare expenditure and stringent government policies, especially within the African region. On the hand, the Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.
BioCardia, Inc. stated in October 2021 that the first patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for refractory angina has been treated in Acute Coronary Syndrome.
The Independent Data Monitoring Committee approved XyloCor Therapeutics' Phase 2 trial of XC001 for refractory angina in July 2021. (IDMC). The greatest dose was given to three people with refractory angina in this study.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | 2032: 15.2 Billion |
| CAGR | 5.3% (2023-2032) |
| Base Year | 2022 |
| Forecast Period | 2023-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnosis, Treatment and End-User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.) |
| Key Market Opportunities | Increasing healthcare expenditure increasing availability of funds for research |
| Key Market Drivers | The increasing prevalence of coronary heart disease Growing geriatric population Growing obese population |
Acute Coronary Syndrome Market Highlights:
Frequently Asked Questions (FAQ) :
Acute Coronary Syndrome Market is projected to grow at a 5.3% CAGR between 2023-2032.
The Americas is expected to lead the Acute Coronary Syndrome Market.
Different end users of Acute Coronary Syndrome Market include academic institutes, diagnostic centers, hospitals and clinics, and others.
Growing obese population and rising prevalence of diabetes is adding market growth.
High cost and lack of awareness may limit market growth.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
